Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer ConferenceGlobeNewswire (press release)PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announce… Continue reading
BGI, University of Manchester Launch Synthetic Biology CollaborationGenetic Engineering & Biotechnology NewsBGI and the University of Manchester have launched a five-year collaboration focused on synthetic biology and metabolic engineering. The partner… Continue reading
Xconomy |
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up
Xconomy The Cambridge, MA, company, seeded last year by a subsidiary of the nonprofit group CureDuchenne, will use a $40 million Series A round led by The Column Group to advance a Duchenne treatment using the gene editing technology CRISPR-Cas9. |
|
Internship ‘bridges’ students to professional stem cell researchers
Daily Aztec The internship program, called the Bridges to Stem Cells Research Internship Program, provides students with the chance to work in a professional lab setting and complete extensive, year-long research on stem cells, said Susan Kaiser, the program’s … |
|
Re-engineered T Cells Show Promise in Fighting HIV
MD Magazine The proteins, called chimeric antigen receptors (CARs), are designed to fight specific diseases (in this case, HIV). The technique involves taking a patient’s blood sample and then re-engineering the T cells in a lab to express disease-specific CARs … |
|
ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and …
Business Wire (press release) DUBLIN & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual … |